Is DaVita (DVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Aug 6, 2026

DaVita Q2 Earnings Call Highlights

DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.

MarketBeat • Aug 5, 2026

DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth

DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.

Zacks Investment Research • Aug 5, 2026

DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.

Zacks Investment Research • Aug 5, 2026

DaVita flags lower revenue per treatment, reaffirms annual forecast

DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining ​enrollments for dialysis treatments as patients dropped ‌out of Obamacare plans following the end of pandemic-era subsidies.

Reuters • Aug 4, 2026

DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript

DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

DaVita Inc. 2nd Quarter 2026 Results

DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results," said Javier Rodriguez, CEO of DaVita Inc. "As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.

PRNewsWire • Aug 4, 2026

DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates

DaVita HealthCare (DVA) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $4.01 per share. This compares to earnings of $2.95 per share a year ago.

Zacks Investment Research • Aug 4, 2026

Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?

DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.

Zacks Investment Research • Aug 3, 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.

Zacks Investment Research • Jul 29, 2026